Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roger Lyons

Hematology San Antonio, TX Medical Doctor

NPI 1508838285 CMS profile 204594

5206 Research Dr, San Antonio, TX 78240

Open in the dashboard

General payments

$43,585

345 records reported · program years 2019–2025

Research payments

$73,129

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,784,681 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Roger Lyons of San Antonio, TX is reported in the CMS Open Payments database as having received $43,585 across 345 general payments and $73,129 in research payments paid to them. Separately, studies naming them as principal investigator received $2,784,681 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $350 3
2024 General $689 6
2023 General $7,179 8
2023 Research $1,235 1
2022 General $10,288 11
2021 General $5,393 4
2021 Research $873 2
2020 General $12,528 33
2019 General $7,157 280
2019 Research $71,021 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roger Lyons
  • Hematology median
  • Middle half of Hematology
  • National median

In program year 2025, general payments to Roger Lyons were reported at $350. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.

Show as a table
Year Roger Lyons Hematology median Middle half National median
2019 $7,157 $1,012 $122–$9,834 $163
2020 $12,528 $1,475 $115–$9,198 $114
2021 $5,393 $1,470 $125–$7,444 $132
2022 $10,288 $1,371 $139–$8,471 $149
2023 $7,179 $1,295 $147–$11,010 $160
2024 $689 $1,286 $146–$9,230 $164
2025 $350 $1,155 $135–$8,023 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $13,433 24 payments
  2. Incyte Corporation $13,161 25 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $3,241 3 payments
  4. UCB, Inc. $2,450 1 payment
  5. Dova Pharmaceuticals $2,404 5 payments
  6. Taiho Oncology, Inc. $2,310 1 payment
  7. E.R. Squibb & Sons, L.L.C. $593 33 payments
  8. Genentech USA, Inc. $561 48 payments
  9. Genzyme Corporation $404 11 payments
  10. AstraZeneca Pharmaceuticals LP $399 8 payments
  11. Other $4,628 186 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $27,181 11 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,647 4 payments
  3. Food and Beverage $7,582 317 payments
  4. Travel and Lodging $971 6 payments
  5. Education $203 7 payments
Products named General payments · program years 2019–2025
  1. PROMACTA $5,599 13 payments
  2. INQOVI $2,310 1 payment
  3. Doptelet $2,250 1 payment
  4. KEYTRUDA $335 19 payments
  5. OPDIVO $279 21 payments
  6. COPIKTRA $248 9 payments
  7. XGEVA $237 11 payments
  8. TECENTRIQ $228 17 payments
  9. DARZALEX $218 7 payments
  10. JAKAFI $206 7 payments
  11. Other $6,351 323 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $51,716 8 payments
  2. Celgene Corporation $13,319 1 payment
  3. Amgen Inc. $5,987 1 payment
  4. Novartis Pharmaceuticals Corporation $2,108 3 payments

Records

358 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record